- Home
- BCAT vs PGEN Comparison
BCAT vs PGEN Comparison
Compare BCAT & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAT | PGEN |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BCAT | PGEN |
|---|---|---|
| Price | $15.26 | $4.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 519.2K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | $10.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.73 | $1.23 |
| 52 Week High | $15.41 | $5.47 |
Technical Indicators
Market Signals| Indicator | BCAT | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 66.14 | 54.94 |
| Support Level | $14.49 | $3.91 |
| Resistance Level | $15.31 | $4.31 |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 94.19 | 64.01 |
Price Performance
Historical ComparisonAbout BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.